Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Larotrectinib Elicits Durable Responses, Extends Survival in TRK+ Sarcomas

January 11th 2021

January 11, 2021 - Larotrectinib was found to induce a high response rate with long durability and improve survival in patients with TRK-positive sarcomas, according to results from an analysis of 3 clinical trials.

Osimertinib/Bevacizumab Improves ORR, But Fails to Prolong PFS in EGFR T790M+ NSCLC

January 8th 2021

January 8, 2021 — The combination of osimertinib plus bevacizumab failed to result in a statistically significant improvement in progression-free survival versus osimertinib alone in patients with advanced lung adenocarcinoma that harbored an EGFR T790M mutation.

FDA Grants Fast Track Designation to Zenocutuzumab for Metastatic NRG1+ Solid Tumors

January 8th 2021

January 8, 2021 — The FDA has granted a fast track designation to zenocutuzumab for the treatment of patients with metastatic solid tumors that harbor NRG1 gene fusions and have progressed on standard-of-care treatment.

Approval for Amivantamab Sought in Europe for Metastatic EGFR Exon 20+ NSCLC

January 4th 2021

January 4th, 2021 - A marketing authorization application has been submitted to the European Medicines Agency for the approval of amivantamab as a treatment for patients with metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations who have experienced disease progression following platinum-based chemotherapy.

EU Approval Sought for Sotorasib in KRAS G12C–Mutated Advanced or Metastatic NSCLC

January 4th 2021

January 4, 2021 - A marketing authorization application has been submitted to the European Medicines Agency for the use of sotorasib in patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer.

Manochakian Breaks Down Barriers to Genetic Testing in Lung Cancer

January 4th 2021

Rami Manochakian, MD, underscores the importance of looking for actionable alterations in lung cancer, barriers to genetic testing, and what is needed to overcome them.

Role for Somatic, Inherited Genetic Testing in Prostate Cancer Continues to Grow

January 3rd 2021

Leonard G. Gomella, MD, discusses the growing importance of genetic testing in prostate cancer.

Matching Novel Targets to Treatment Generates Excitement in TNBC

December 31st 2020

Neelima Vidula, MD, discusses the current and future utility of PARP inhibitors in triple-negative breast cancer, the promise of sacituzumab govitecan, and the need for germline genetic testing.

Pinpointing the Need for Genetic Testing in Oncology

December 31st 2020

Phuong L. Mai, MD, discusses the situations in which genetic testing should be considered and the importance of bridging awareness and access within oncology.

Learning to Tailor Targeted and Immune Therapy in Lung Cancer

December 14th 2020

Faculty of the MedStar Georgetown University Hospital-hosted Institutional Perspectives in Cancer webinar on lung cancer spotlight key advances made with targeted therapies in lung cancer, the ways in which immunotherapy has complicated treatment decisions, and more!

Expert Expands on Recent Advances With Actionable Alterations Spanning GI Cancers

December 7th 2020

Nathan Bahary, MD, PhD, discusses the importance of seeking targetable alterations in GI cancers, as well as recent advancements in the space.

Fruquintinib Enters Phase 3 Trial for Metastatic Colorectal Cancer

December 7th 2020

December 7, 2020 - The survival benefit of the novel agent fruquintinib will be tested during the phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer who are either intolerant to or have received 3 prior lines of chemotherapy.

Dr. Flaherty on the Significance of the NCI-MATCH Precision Medicine Trial

December 5th 2020

Keith T. Flaherty, MD, discusses the significance of the NCI-MATCH study.

Dr. Olopade on Moving the Needle Forward in Preventive Oncology and Genetics

December 5th 2020

Olufunmilayo I. Olopade, MD, FACP, discusses the need to focus efforts in preventive oncology and genetics.

Understanding Biomarker Differences Becomes Critical as Precision Medicine Rises in Melanoma

December 4th 2020

Jason J. Luke, MD, FACP discusses the role of precision medicine and how it continues to lead the way in all areas of oncology, but especially in melanoma.

Huntsman Homes in on the Integration of Precision Medicine in Oncology

December 3rd 2020

In our exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.

Need for Genetic Testing Becomes More Pronounced in Breast, Gynecologic Cancers as Targeted Approaches Abound

December 2nd 2020

Lan G. Coffman, MD, PhD, discusses the role of genetic testing in breast and gynecologic cancers and the many advances made with targeted therapies.

Novel Tubulin-Targeting Therapies Make Headway

November 30th 2020

Clinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.

FDA Approves Naxitamab-gqgk for Relapsed/Refractory High-Risk Neuroblastoma

November 25th 2020

The FDA has approved naxitamab-gqgk (Danyelza) for use in combination with granulocyte-macrophage colony-stimulating factor as a treatment for pediatric patients 1 year of age and older and adult patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior treatment.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.